Dogwood Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Details)

Stockholders' Equity (Details)					1 Months Ended	3 Months Ended
Stockholders' Equity (Details)	Jan. 11, 2026 USD ($) $ / shares shares	Nov. 21, 2025 shares	Mar. 12, 2025 USD ($) $ / shares shares	Oct. 17, 2024	Sep. 30, 2025 USD ($) shares	Mar. 31, 2026 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) shares	Apr. 30, 2026 USD ($)	Apr. 21, 2026 USD ($)	Mar. 11, 2026 shares	Jan. 15, 2026 $ / shares shares	Jan. 09, 2026 USD ($)	Dec. 31, 2025 USD ($) $ / shares shares	Nov. 28, 2025 USD ($)	Sep. 29, 2025 $ / shares	Oct. 31, 2024 shares	Oct. 07, 2024 $ / shares	Dec. 31, 2023 $ / shares shares	Dec. 16, 2020 $ / shares shares
Stockholders' Equity
Preferred stock authorized																2,000,000		2,000,000
Preferred stock, par value (in dollars per share) \| $ / shares																		$ 0.0001
Temporary equity, shares authorized						2,104							2,104
Temporary equity, shares issued						0							0
Temporary equity, shares outstanding						0							0
Waiver of cash settlement and related repurchase rights for series A preferred stock					166
Waiver and conversion of preferred stock \| $					$ 5,500,000
Contingent value rights liability \| $						$ 0
Common stock authorized						43,000,000							43,000,000						43,000,000
Common stock, par value (in dollars per share) \| $ / shares						$ 0.0001							$ 0.0001						$ 0.0001
Net proceeds from issuance of common stock \| $						$ 11,397,459	$ 4,372,378
Deferred issuance costs \| $												$ 159,000	$ 158,956
Pre-funded Warrants
Stockholders' Equity
Warrants exercise price \| $ / shares						$ 0.0001					$ 0.0001
Warrants to purchase shares											2,047,089
Common Warrants
Stockholders' Equity
Offering price per share \| $ / shares											$ 3.28
Warrants exercise price \| $ / shares						$ 3.28
Warrants exercise period						5 years 6 months
Warrants to purchase shares										4,386,037	4,386,037
Number of warrants issued along with each common stock or warrant	1
Subsequent Event
Stockholders' Equity
Maximum potential payments \| $								$ 100,000,000	$ 100,000,000
Percentage of royalty on net sales								15.00%	15.00%
Percentage of Series A financing receivable								10.00%	10.00%
Percentage of financing receivable except Series A financing								9.00%	9.00%
Preferred Stock Excluding Series A and Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized						1,997,254							1,997,254
Series A preferred stock
Stockholders' Equity
Preferred stock converted to common stock		10,000
Temporary equity, shares authorized						2,270							2,270			2,270
Temporary equity, shares issued						0							0
Temporary equity, shares outstanding						0							0
Series A1 Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized						285	285						285
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Preferred stock issued						0							0
Preferred stock outstanding						0							0
Preferred stock converted to common stock		10,000
Convertible Preferred Stock, Shares Issued upon Conversion			10,000
Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized						285							285
Preferred stock, par value (in dollars per share) \| $ / shares						$ 0.0001							$ 0.0001
Preferred stock issued						0							0
Preferred stock outstanding						0							0
Common stock, par value (in dollars per share) \| $ / shares															$ 0.0001
Series A2 Convertible Preferred stock
Stockholders' Equity
Preferred stock authorized					190.0572	190.0572							190.0572
Preferred stock issued						0							0
Preferred stock outstanding						0							0
Preferred stock converted to common stock		10,000
Series A-2 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized						190.0572							190.0572
Preferred stock, par value (in dollars per share) \| $ / shares						$ 0.0001							$ 0.0001
Preferred stock issued						0							0
Preferred stock outstanding						0							0
Common stock, par value (in dollars per share) \| $ / shares															0.0001
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized						166							166
Preferred stock, par value (in dollars per share) \| $ / shares						$ 0.0001							$ 0.0001
Preferred stock issued						0							0
Preferred stock outstanding						0							0
Common stock, par value (in dollars per share) \| $ / shares															$ 0.0001
Pharmagesic Holdings Inc.
Stockholders' Equity
Preferred stock, par value (in dollars per share) \| $ / shares																	$ 0.0001
Number of contingent value rights issuable for each common share				1
Contingent value rights agreement term				7 years
Percentage of upfront payment to which holders are entitled				87.75%
Percentage ownership of outstanding rights that entitles holder to audit and enforcement				30.00%
At the market offering
Stockholders' Equity
Aggregate offering price \| $														$ 8,558,712
January 2026 Offering
Stockholders' Equity
Offering price per share \| $ / shares	$ 2.85
Net proceeds from issuance of common stock \| $						$ 11,400,000
Offering price \| $ / shares	$ 2.8499
Gross proceeds \| $	$ 12,500,000
January 2026 Offering \| Pre-funded Warrants \| Maximum
Stockholders' Equity
Warrants to purchase shares	2,047,089
January 2026 Offering \| Common Warrants
Stockholders' Equity
Additional Gross Proceeds Receivable From Warrant Exercises \| $	$ 14,400,000
January 2026 Offering \| Common Warrants \| Maximum
Stockholders' Equity
Warrants to purchase shares	4,386,037
Registered Direct Offering
Stockholders' Equity
No of shares issued	2,338,948		578,950
Offering price per share \| $ / shares			$ 8.26
Gross proceeds from issuance of shares \| $			$ 4,780,000
Net proceeds from issuance of common stock \| $			$ 4,250,000
Private Offering \| Pre-funded Warrants
Stockholders' Equity
Warrants to purchase shares	2,047,089
Private Offering \| Common Warrants
Stockholders' Equity
Warrants to purchase shares	4,386,037									4,386,037